Patents Examined by Noble E Jarrell
  • Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
    Patent number: 10398665
    Abstract: An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. An exemplary embodiment provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ?F508-CFTR, or another mutation of class II.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: September 3, 2019
    Assignee: INSTYTUT BIOCHEMII I BIOFIZYKI PAN
    Inventors: Norbert Odolczyk, Piotr Zielenkiewicz, Grzegorz Wieczorek, Aleksander Edelman, Danielle Tondelier, Janine Fritsch
  • Prevention and treatment of non-alcoholic fatty liver disease
    Patent number: 10392381
    Abstract: Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective amount of at least one compound of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof. The pharmaceutical composition includes at least one compound of the General Formula (I) or the General Formula (II) for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: August 27, 2019
    Assignee: Ohio University
    Inventors: Kelly D. McCall, Frank L. Schwartz, Douglas J. Goetz
  • Nitrogen-containing aromatic compounds and metal complexes
    Patent number: 10392395
    Abstract: To provide nitrogen-containing aromatic compounds with excellent oxygen reduction activity, metal complexes containing them, and catalysts and electrodes employing the same, the present invention provides an aromatic compound satisfying the following conditions (a) and (b): (a) It has 2 or more structures surrounded by at least 4 coordinatable nitrogen atoms (which structures may be the same or different), (b) At least one of the nitrogen atoms composing the structure is a nitrogen atom in a 6-membered nitrogen-containing heterocyclic ring.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 27, 2019
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Nobuyoshi Koshino, Hideyuki Higashimura, Klaus Muellen, Christian von Malotki, Qi Su, Martin Baumgarten, Hassan Norouzi-Arasi, Lena Arnold, Ruili Liu
  • Process for the synthesis of intermediates of Nebivolol
    Patent number: 10392361
    Abstract: The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl)chromans of formula I. The intermediates thus obtained can be used for the synthesis of Nebivolol.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: August 27, 2019
    Assignee: Menarini International Operations Luxembourg S.A.
    Inventors: Sandra Bartoli, Serena Mannucci, Alessio Griselli, Alessio Stefanini
  • Synthetic route to anhydroryanodol, ryanodol and structural analogues
    Patent number: 10392360
    Abstract: This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogs thereof and novel compounds prepared thereby.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 27, 2019
    Assignee: California Institute of Technology
    Inventors: Sarah Reisman, Kangway V. Chuang, Chen Xu
  • Histone demethylase inhibitors
    Patent number: 10385047
    Abstract: The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: August 20, 2019
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Amogh Boloor, Young K. Chen, Michael Brennan Wallace
  • Macrocyclic LRRK2 kinase inhibitors
    Patent number: 10377772
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 13, 2019
    Assignee: Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Potent soluble epdxide hydrolase inhibitors
    Patent number: 10377744
    Abstract: The invention discloses a new series of inhibitors of soluble epoxide hydrolase (sEH) with improved physical properties that enhance their druglikeness to treat sEH associated diseases such as chronic diabetic neuropathic pain.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: August 13, 2019
    Assignee: Eicosis, LLC
    Inventors: Bruce D. Hammock, Kin Sing Stephen Lee, Ahmet Bora Inceoglu
  • Vinblastine derivatives, preparation method therefor and application thereof
    Patent number: 10377774
    Abstract: The present invention provides a new kind of vinca alkaloid derivatives, new applications thereof and preparation methods therefor. The vinca alkaloid derivatives comprise hydrazinolyzed vinca alkaloids and vinca alkaloid dipeptide derivative. The hydrazinolyzed vinca alkaloids are the compounds obtained from the reaction of vinca alkaloids or salts thereof with hydrazinolyzed hydrate; and the vinca alkaloid dipeptide derivatives are the compounds obtained from the condensation of hydrazinolyzed vinca alkaloids with N-benzyloxycarbonylglycyl proline. The present invention provides the uses of the vinca alkaloids derivatives or the pharmaceutical compositions thereof in anti-tumor, preventing or treating diabetic retinopathy, rheumatoid arthritis and serving as angiogenesis inhibitors or vascular disrupting agents.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: August 13, 2019
    Assignee: JINAN UNIVERSITY
    Inventors: Wencai Ye, Heru Chen, Dongmei Zhang, Minfeng Chen, Nanhui Xu
  • Process for preparing aminotetrahydropyrans
    Patent number: 10377732
    Abstract: The present invention relates to a process for preparing 3-amino tetrahydropyrans and, more particularly, to an improved method for synthesizing a 2,3,5-substituted tetrahydropyran derivative, intermediate being used in the preparation of dipeptidyl peptidase-IV enzyme inhibitors (DPP-4 inhibitors).
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 13, 2019
    Assignee: F.I.S.—Fabbrica Italiana Sintetici S.p.A.
    Inventors: Paolo Maragni, Massimo Verzini
  • 4-(2-amino-tetrahydronaphthalenyl)pyrimidine derivative, preparation method therefor, and pharmaceutical composition for preventing or treating cancer, containing same as active ingredient
    Patent number: 10369149
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 6, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Hyoung Rae Kim, Jae Du Ha, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Chang Soo Yun, Chong Ock Lee, Chi Hoon Park, Chong Hak Chae, Sunjoo Ahn
  • Super-oxide dismutase mimetics
    Patent number: 10350193
    Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide. It also relates to methods of using these complexes to reduce the concentration or the effects of superoxide, pharmaceutical compositions comprising these compounds or their metal complexes, and methods of treating conditions associated with excessive superoxide activity.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 16, 2019
    Assignee: Galera Labs, LLC
    Inventor: Dennis P. Riley
  • Lactate dehydrogenase inhibitor and antiepileptic drug containing the same
    Patent number: 10350192
    Abstract: The invention provides a lactate dehydrogenase inhibitor that makes it possible to suppress refractory epilepsy in which conventional antiepileptic drugs are ineffective, and an antiepileptic drug containing said inhibitor. The lactate dehydrogenase inhibitor of the invention contains a compound represented by formula (III); i.e., isosafrole or a compound having isosafrole as a scaffold, and the antiepileptic drug of the invention has these compounds as an active ingredient.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: July 16, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Tsuyoshi Inoue, Nagisa Sada
  • Macrocyclic complexes, their process of preparation and use as PET imaging agents
    Patent number: 10351539
    Abstract: The present invention concerns compounds of formula (I): their process of preparation and compositions thereof. The present invention also concerns their use as diagnostic agent in PET imaging.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: July 16, 2019
    Assignees: INSERM (Institut National de la Santé et de le Recherche Médicale), Université d'Auvergne Clermont 1
    Inventors: Claire Denis, Vincent Gaumet, Aurélien Vidal, Philippe Auzeloux, Jean-Claude Madelmont, Elisabeth Miot-Noirault, Jean-Michel Chezal
  • Color material dispersion liquid for color filter, color resin composition for color filter, color material, color filter, liquid crystal display device, and light-emitting display device
    Patent number: 10351705
    Abstract: Disclosed is a color material dispersion liquid for a color filter, the dispersion liquid being capable of forming a high-luminance coating film with excellent light resistance; a color resin composition for a color filter, the composition being capable of forming a high-luminance coating film with excellent light resistance; a color material that has, while it can form a high-luminance coating film, excellent light resistance; a high-contrast, high-luminance color filter; a liquid crystal display device including the color filter; and a light-emitting display device including the color filter. The color material dispersion liquid for a color filter, includes: (A) a color material, (B) a dispersant and (C) a solvent, wherein the color material (A) contains a cerium lake color material of an acid dye.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: July 16, 2019
    Assignee: Dai Nippon Printing Co., Ltd.
    Inventors: Fumiyasu Murakami, Michihiro Ogura, Tomoki Murata, Daisuke Endo
  • Material for organic electroluminescent device and organic electroluminescent device using the same
    Patent number: 10347844
    Abstract: A novel and improved material for an organic electroluminescent device includes at least one monoamine compound represented by any one of the following Formulae I to III: In Formulae I to III, Ar is a substituted or unsubstituted aryl group having 6 to 50 carbon atoms for forming a ring. The organic electroluminescent device including the material may have improved emission life.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: July 9, 2019
    Assignee: Samsung Display Co., Ltd.
    Inventors: Hideo Miyake, Ichinori Takada, Hiromi Nakano
  • Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile
    Patent number: 10336698
    Abstract: A new process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile is described. This compound can be used for the production of drugs, such as Fexofenadine.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: July 2, 2019
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hermut Wehlan, Kai Rossen, Alexander Schaefer
  • Monomer, organic layer composition, organic layer, and method of forming patterns
    Patent number: 10332751
    Abstract: A monomer, an organic layer composition including the monomer, an organic layer, and a method of forming patterns, the monomer being represented by Chemical Formula 1:
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: June 25, 2019
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Yoo-Jeong Choi, Yun-Jun Kim, Yu-Shin Park, You-Jung Park, Hyun-Ji Song
  • Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
    Patent number: 10328157
    Abstract: Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 25, 2019
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventor: Robert Yongxin Zhao
  • Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK
    Patent number: 10323043
    Abstract: The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 18, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: El Bachir Kaloun, Serge Grisoni, Anna Kruczynski, Philippe Schmitt